MyFinsight
Home
Blog
About
Cash and cash
equivalents
$6,660,170
(9.88%↑ Y/Y)
Prepaid expenses & other
current assets
$1,097,664
(-15.50%↓ Y/Y)
Marketable securities
$701,085
(-92.88%↓ Y/Y)
Total current assets
$8,458,919
(-50.82%↓ Y/Y)
Deferred offering costs
$54,827
Operating lease
right-of-use assets
$38,242
(-73.30%↓ Y/Y)
Other assets
$26,090
(-28.98%↓ Y/Y)
Property and equipment,
net
$24,271
(-38.59%↓ Y/Y)
Total assets
$8,602,349
(-50.62%↓ Y/Y)
Accumulated deficit
-$103,546,350
(-21.97%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$39,759
(-182.76%↓ Y/Y)
Total liabilities and
stockholders (deficit)...
$8,602,349
(-50.62%↓ Y/Y)
Total stockholders
(deficit) equity
-$3,217,252
(-125.69%↓ Y/Y)
Additional paid-in capital
$100,367,581
(3.08%↑ Y/Y)
Common stock
(25,000,000 authorized at...
$1,276
(18.37%↑ Y/Y)
Total liabilities
$11,819,601
(141.32%↑ Y/Y)
Warrant liability
$7,497,089
Total current
liabilities
$4,322,512
(-11.50%↓ Y/Y)
Accounts payable and
accrued expenses
$4,282,797
(-9.89%↓ Y/Y)
Operating lease
liabilities, current
$39,715
(-69.80%↓ Y/Y)
Back
Back
Balance Sheet
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)
source: myfinsight.com